# Increasing Dose Tolerance Study in Healthy Male Volunteers After Administration of BIII 890 CL

> **NCT02268136** · PHASE1 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 76 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BIII 890 CL
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02268136
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1999-04
- **Primary completion:** 1999-12
- **Final completion:** —
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2014-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02268136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02268136, "Increasing Dose Tolerance Study in Healthy Male Volunteers After Administration of BIII 890 CL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02268136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*